Aberdeen Group’s Tandem Diabetes Care TNDM Stock Holding History

Aberdeen Group’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.67M	Buy	441,738 +7,711	+2%	+$135K	0.01%	661
2026 Q1	$8.32M	Sell	434,027 -113,008	-21%	-$2.46M	0.01%	620
2025 Q4	$12M	Sell	547,035 -51,061	-9%	-$922K	0.02%	577
2025 Q3	$7.26M	Buy	598,096 +241,878	+68%	+$3.27M	0.01%	653
2025 Q2	$6.64M	Hold	356,218	–	–	0.01%	673
2025 Q1	$6.83M	Buy	356,218 +107,354	+43%	+$3.14M	0.01%	643
2024 Q4	$8.96M	Buy	248,864 +104,413	+72%	+$3.53M	0.02%	531
2024 Q3	$6.13M	Buy	+144,451	New	+$6.12M	0.01%	619

Other funds holding TNDM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Aberdeen Group's TNDM Position: Q2 2026 in Review

Aberdeen Group increased its Tandem Diabetes Care (TNDM) stake by 1.8% in Q2 2026, buying an estimated $135K and bringing the position to 441,738 shares worth $6.67M. The position accounts for 0.01% of the portfolio, ranked #661.

Aberdeen Group first reported a position in TNDM in Q3 2024 and has held it in 8 quarters since. The position peaked at $12M in Q4 2025. 274 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.

Aberdeen Group held 441,738 shares of Tandem Diabetes Care worth $6.67M as of Q2 2026.
Aberdeen Group bought 7,711 Tandem Diabetes Care shares in Q2 2026, an estimated $135K.
Tandem Diabetes Care made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #661 holding.
Aberdeen Group first reported a position in Tandem Diabetes Care in Q3 2024 and has held it in 8 quarters since.
Aberdeen Group's Tandem Diabetes Care position peaked at $12M in Q4 2025.
274 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.